Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

(2015) L Gossec et al.   ANNALS OF THE RHEUMATIC DISEASES

Enhanced Patient Involvement and the Need to Revise the Core Set -- Report from the Psoriatic Arthritis Working Group at OMERACT 2014

(2015) W. Tillett et al.   JOURNAL OF RHEUMATOLOGY

Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial

(2015) Laura C Coates et al.   LANCET

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

SAT0377 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial

(2014) A. Adebajo et al.   ANNALS OF THE RHEUMATIC DISEASES

Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study

(2014) A Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol

(2013) D van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

(2013) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Application and Modifications of Minimal Disease Activity Measures for Patients with Psoriatic Arthritis Treated with Adalimumab: Subanalyses of ADEPT

(2013) P. J. Mease et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study

(2013) D. Gladman et al.   ARTHRITIS CARE & RESEARCH

Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study

(2012) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

(2012) Arthur Kavanaugh et al.   ARTHRITIS AND RHEUMATISM

A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

(2012) Gabrielle H. Kingsley et al.   RHEUMATOLOGY

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study

(2011) Asta Baranauskaite et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

(2011) D. van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

(2011) Zoe Ash et al.   ANNALS OF THE RHEUMATIC DISEASES

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

(2011) L Gossec et al.   ANNALS OF THE RHEUMATIC DISEASES

Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens

(2011) R. Gniadecki et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Clinical outcomes in psoriatic arthritis: A systematic literature review

(2011) Penélope Esther Palominos et al.   ARTHRITIS CARE & RESEARCH

Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study

(2010) F. Atzeni et al.   ANNALS OF THE RHEUMATIC DISEASES

Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial

(2010) JC Prinz et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment

(2009) L C Coates et al.   ANNALS OF THE RHEUMATIC DISEASES

When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?

(2008) J. S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES